Calidi Biotherapeutics Inc. (NYSE American: CLDI), a clinical-stage biotechnology firm focused on developing advanced antitumor virotherapies, has announced that its research abstract titled “Development of a Systemic Enveloped Virotherapy for Targeting All Metastatic Sites” will be presented at the American Association for Cancer Research (AACR) Annual Meeting scheduled for April 25-30, 2025, in Chicago, Illinois.
This presentation marks a pivotal moment for Calidi as it continues to push the boundaries of systemic enveloped virotherapy, aiming to address the pressing challenge of metastatic cancers, which are responsible for the majority of cancer-related deaths. The data shared will emphasize the capabilities of Calidi’s proprietary RTNova platform, which is designed to facilitate targeted systemic delivery to various tumor sites while evading rapid elimination by the immune system.
The RTNova platform is particularly significant for treating advanced-stage metastatic cancers, such as lung cancer, where traditional intratumoral administration methods may not be viable. Calidi has engineered a unique strain of vaccinia virus that is enveloped with a human cell membrane (referred to as an extracellular enveloped virus or EEV). This innovative design not only protects the virus during its journey through the body but also enhances its ability to target distant tumors. Once it reaches the tumor site, the virus stimulates a robust immune response from the patient’s own immune cells, potentially leading to longer-lasting therapeutic effects.
Allan Camaisa, CEO and Chairman of Calidi Biotherapeutics, expressed enthusiasm about the upcoming presentation: “Our acceptance to present at AACR underscores the transformative potential of our systemic virotherapy platform. We are eager to share our groundbreaking research on RTNova, which could redefine treatment approaches for metastatic cancers and significantly enhance patient outcomes.”
In addition to its participation at AACR, Calidi is preparing to submit another abstract for presentation at the ASCO Annual Meeting in June 2025. This forthcoming presentation will provide further insights into the progress made in selecting a lead clinical candidate for RTNova. These efforts complement Calidi’s existing clinical and preclinical initiatives involving localized and intratumoral cell-based virotherapies under its SNV (SuperNova) and NNV (NeuroNova) platforms.
Calidi Biotherapeutics is dedicated to revolutionizing cancer treatment through its proprietary immuno-oncology technologies. The company specializes in harnessing potent allogeneic stem cells capable of delivering oncolytic viruses across various oncology indications, including high-grade gliomas and solid tumors. Its innovative off-the-shelf delivery platforms are designed to protect and amplify these therapeutic agents while enhancing efficacy and patient safety.
Calidi Biotherapeutics is committed to advancing its dual approach of using preclinical enveloped virotherapies aimed at targeting disseminated solid tumors. This strategy holds promise for treating and potentially preventing metastatic disease.
